Article
Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2011
Wong Harvey, Alicke Bruno, West Kristina A, Pacheco Patricia, La Hank, Januario Tom, Yauch Robert L, de Sauvage Frederic J, Gould Stephen E
Abstract excerpt
PURPOSE: Vismodegib (GDC-0449) is a potent and selective inhibitor of the Hedgehog (Hh) pathway that shows antitumor activity in preclinical models driven by mutational or ligand-dependent activation of the Hh pathway. We wished to characterize the pharmacokinetic-pharmacodynamic (PK/PD) relationship of vismodegib in both model systems to guide optimal dose and schedule for vismodegib in the clinic. EXPERIMENTAL...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.